FDA Approval: Whos Being Harmed & Whos Being Helped? Presented - - PowerPoint PPT Presentation

fda approval who s being
SMART_READER_LITE
LIVE PREVIEW

FDA Approval: Whos Being Harmed & Whos Being Helped? Presented - - PowerPoint PPT Presentation

FDA Approval: Whos Being Harmed & Whos Being Helped? Presented by: Diana Zuckerman, PhD President Cancer Prevention and Treatment Fund of the National Research Center for Women & Families Sahru Keiser, MPH Education and


slide-1
SLIDE 1

FDA Approval: Who’s Being Harmed & Who’s Being Helped?

Presented by: Diana Zuckerman, PhD President Cancer Prevention and Treatment Fund of the National Research Center for Women & Families Sahru Keiser, MPH Education and Mobilization Coordinator

slide-2
SLIDE 2

Agenda

 Overview of FDA approval process  FDA approval of drugs and devices  Substantially Equivalent Devices  BCAction’s Position on FDA approval  Ways you can get involved

slide-3
SLIDE 3

Our Mission

Brea east C Canc ncer er A Action n carries es the he voices es o

  • f peo

eople a e affec ected ed b by brea east canc ncer er in o n order er t to i ins nspire e and nd comp mpel el t the he cha hang nges es nec neces essary t to end end t the b he brea east c canc ncer er ep epidemi emic.

slide-4
SLIDE 4

BCAction’s Strategic Priorities

(1) Putting Patients First (2) Creating Healthy Environments (3) Eliminating Social Inequities

slide-5
SLIDE 5

Sahru Keiser, MPH

Education and Mobilization Coordinator Breast Cancer Action

slide-6
SLIDE 6

Diana Zuckerman, PhD

President Cancer Prevention and Treatment Fund of the National Research Center for Women & Families

slide-7
SLIDE 7

FDA Approval: Who is being Harmed And Who is being Helped?

Diana Zuckerman, PhD President

National Research Center for Women & Families

slide-8
SLIDE 8

Statistical Evidence

There are 3 kinds of lies: Lies, damn Lies, and statistics

slide-9
SLIDE 9

Objective Studies?

  • Research shows that the source of

funding influences study

  • utcomes.
  • When companies pay for studies,

published results tend to reflect their financial interests

slide-10
SLIDE 10

Does FDA Approval = Safety?

Criteria for Approval of Prescription Drugs:

  • Safe (over the short-term)
  • Effective (compared to placebo)
  • Lack of data on dangers is NOT sufficient

CAVEAT: companies pay for the studies but the FDA reviews the data

slide-11
SLIDE 11

FDA Approval of Drugs

Safe and Effective does NOT mean

  • Nobody will die from this drug
  • Nobody will be harmed by this drug
  • This drug is safe for long-term use
  • This drug was tested on people of color
  • This drug is more effective than other OR

cheaper drugs on the market

slide-12
SLIDE 12

What Medications Don’t Require FDA Approval

Criteria for Dietary Supplements and Compounding Pharmacies

  • Not tested for Safety
  • Not proven Effective
  • Lack of data on dangers IS sufficient
slide-13
SLIDE 13

FDA Approval of Medical Devices

  • Reasonably Safe
  • Reasonably Effective

OR

  • Substantially Equivalent to other devices on

the market – same use, similar materials-- 98% of devices are approved that way (510 k loophole)

slide-14
SLIDE 14

Low Risk = Not tested

slide-15
SLIDE 15

Moderate Risk (510k)

slide-16
SLIDE 16

High Risk Medical Devices

(pacemaker, heart, infusion pump)

slide-17
SLIDE 17

Example: Radiation Shield

  • The Axxent FlexiShield Mini shapes the

radiation beam. It is a flexible pad placed

  • n the body, made of tungsten and

silicone

  • It was cleared as substantially equivalent

to a lead block attached to a tray

  • Recalled when tungsten was found in the

women’s breasts

slide-18
SLIDE 18

Substantially Equivalent Devices

Mammography

  • 3D mammography machines must be proven

safe and effective

  • Other mammography machines only need

evidence they are substantially equivalent to those already on the market

  • No clinical trials required. No inspections to

make sure they are made correctly

slide-19
SLIDE 19

Are these substantially equivalent?

=

?

slide-20
SLIDE 20

=

Are these substantially equivalent?

Vitek TMJ implants Dow silicone sheet

?

slide-21
SLIDE 21

Are these substantially equivalent?

=

?

slide-22
SLIDE 22

Studies for FDA are Short-term

But some products are used for years, such as Tamoxifen, Hormone Replacement Therapy, Osteoporosis drugs, breast implants, or mammography Approval: Based on short-term studies, PERHAPS with requirement of later long-term studies

slide-23
SLIDE 23

Breast Implants Doctors Focus on Benefits Promise: You’ll feel good about yourself Evidence: Short-term subjective studies

slide-24
SLIDE 24

Implant Complications #1 - Capsular Contracture FDA booklet

slide-25
SLIDE 25

Necrosis in breast cancer patient with implants for one week

slide-26
SLIDE 26

Breast Implant Studies

  • Long term data MIA: 95% of women dropped
  • ut of some post-market studies, but FDA

did not enforce study requirements

  • Implant makers focused on good news: no

breast cancer or lung cancer after 7-10 years!

  • How many smokers get lung cancer at age

27? Cancer often takes 20-30 years to develop.

slide-27
SLIDE 27

Fast Track Drug Reviews

  • Avastin was approved for Stage IV breast

cancer on the basis of delay in cancer progression – not long-term patient health YEARS LATER: After approval, studies showed women taking Avastin lived for a shorter amount of time with a worse quality of life because of stroke and perforations of gastro- intestinal track

slide-28
SLIDE 28

Why are standards lowered?

Lobbyists: $$$ Lobbyists: device companies in every Congressional district Lobbyists: Jobs/ innovation vs. Safety

slide-29
SLIDE 29

Conclusions

  • FDA approval does not mean safe for

everyone

  • Dietary supplements are tested only if they

seem to be dangerous

  • Drugs from compounding pharmacies are

not tested for safety or effectiveness

  • 95% of medical devices are approved without

clinical trials

slide-30
SLIDE 30

Conclusions

  • When studies are required, they are short-

term

  • FDA standards of safety for devices is less

strict than for drugs, and FDA approval for drugs does not always mean they are safe

  • Let the buyer beware
slide-31
SLIDE 31

Diana Zuckerman, PhD President

National Research Center for Women & Families Cancer Prevention and Treatment Fund info@stopcancerfund.org www.center4research.org www.stopcancerfund.org

slide-32
SLIDE 32

BCAction’s position FDA Approval

Treatments should be: More effective Less toxic Less expensive

slide-33
SLIDE 33

Accelerated Approval Process

 What is Accelerated Approval?  Accelerated Approval vs. Compassionate Access  Striking a balance  Examples – Avastin, TDM-1

slide-34
SLIDE 34

Surrogate End Points

 What are they?  Common surrogate marker  Progression free survival vs. Overall survival  Limitations

slide-35
SLIDE 35

What you can do

Individuals

– Empowered and engaged consumer/patient

Systems

– Collective power to influence and change regulatory systems

slide-36
SLIDE 36

Review resources from presentation

 National Research Center for Women and Families www.center4reserach.org  The Cancer Prevention and Treatment Fund www.stopcancerfund.org  The National Women’s Health Network www.nwhn.org  Breast Cancer Action www.bcaction.org

slide-37
SLIDE 37

Join BCAction!

 Signup for BCActions’s newsletter and e-alert www.bcaction.org  Join BCAction on Facebook www.facebook.com/BCAction  Follow BCAction on Twitter twitter.com/BCAction  Spread the word to friends, family, and colleagues  Donate to BCAction (www.bcaction.org/donate)

slide-38
SLIDE 38

Support Our Webinar Series

Your support counts! If you’ve been inspired today, consider making a donation of $25 or more. www.bcaction.org/donate

More questions? Contact us! Email: info@bcaction.org Toll-free: 877-2STOPBC

slide-39
SLIDE 39

Breast Cancer Action

Cha hallengi enging ng Assum ssumpt ptions.

  • ns. I

Inspi nspiring C ng Cha hange. nge.

www.bcaction.org www.thinkbeforeyoupink.org